TransMedics Group, Inc. (TMDX) |
| 116.11 0.43 (0.37%) 04-15 16:00 |
| Open: | 116.41 |
| High: | 117.64 |
| Low: | 115.3868 |
| Volume: | 365,091 |
| Market Cap: | 3,983(M) |
| PE Ratio: | 23.84 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 154.40 |
| Resistance 1: | 132.19 |
| Pivot price: | 106.07 |
| Support 1: | 108.02 |
| Support 2: | 93.08 |
| 52w High: | 156 |
| 52w Low: | 84.53 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| EPS | 4.870 |
| Book Value | 188.100 |
| PEG Ratio | 0.00 |
| Gross Profit | 185107136.000 |
| Profit Margin (%) | 31.43 |
| Operating Margin (%) | 13.23 |
| Return on Assets (ttm) | 7.3 |
| Return on Equity (ttm) | 54.2 |
Tue, 14 Apr 2026
Does TransMedics Group's (TMDX) Cash Flow Turn and Fleet Expansion Reshape Its Capital Allocation Story? - Yahoo Finance
Tue, 14 Apr 2026
TransMedics (TMDX) down 20.3% since last earnings report: Can it rebound? - MSN
Tue, 14 Apr 2026
TransMedics Group, Inc. $TMDX Position Lifted by Baillie Gifford & Co. - MarketBeat
Mon, 13 Apr 2026
TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Fri, 10 Apr 2026
A Look at TransMedics Group Inc (TMDX) After 4.4% Gain -- GF Value $177.87 vs Price $114.00 - GuruFocus
Tue, 07 Apr 2026
TransMedics Group (TMDX) Is Up 11.1% After Earnings Beat On Organ Perfusion Demand Has The Bull Case Changed? - simplywall.st
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |